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The HIV-1 reservoir is the major hurdle to curing HIV-1. However, the impact of the viral
genome on the HIV-1 reservoir, i.e. its heritability, remains unknown. We investigate the
heritability of the HIV-1 reservoir size and its long-term decay by analyzing the distribution of
those traits on viral phylogenies from both partial-pol and viral near full-length genome
sequences. We use a unique nationwide cohort of 610 well-characterized HIV-1 subtype-B
infected individuals on suppressive ART for a median of 5.4 years. We find that a moderate
but significant fraction of the HIV-1 reservoir size 1.5 years after the initiation of ART is
explained by genetic factors. At the same time, we find more tentative evidence for the
heritability of the long-term HIV-1 reservoir decay. Our findings indicate that viral genetic
factors contribute to the HIV-1 reservoir size and hence the infecting HIV-1 strain may affect
individual patients’ hurdle towards a cure.
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Combination antiretroviral therapy (ART) can effectivelyblock HIV-1 replication and reduce plasma virus levels tobelow the detection limit of clinical assays1. However,
treatment cannot eradicate HIV-1 due to the existence of the
extremely slowly decaying HIV-1 reservoir2,3. The HIV-1 reser-
voir refers to the proviral HIV-1 DNA that persists mainly in
infected resting memory CD4+ T cells throughout the body4,
including the brain, lymph nodes, blood, and digestive tract. It is
established already early during primary infection and persists
even in patients under long-term ART with no detectable
viremia2,5–7. Thus, the HIV-1 reservoir is recognized as a major
hurdle to complete viral eradication.
As individuals with smaller HIV-1 reservoirs should be more
amenable to cure, several studies have assessed the potential
clinical, immunological, and epidemiological determinants of
HIV-1 reservoir size. Early ART initiation limits the HIV-1
reservoir size8–10. Also, pre-treatment viral load correlates posi-
tively with reservoir size3,11. Immunological factors such as
homeostatic proliferation12, clonal expansion13–15, and initial
antiviral immune responses16,17 and epidemiological factors such
as transmission group and ethnicity3 also play a role. The decay
of the HIV-1 reservoir in individuals on ART and its potential
determinants were only examined in a few studies2,3,18–22.
Recently, the frequency of blips has also been associated with the
size and a slower decay of the HIV-1 reservoir3 and whether
cryptic replication plays a role in refilling the reservoir has been
an ongoing debate for decades4. Generally, a small to zero decay
slope was reported, and viral blips were confirmed to slow down
the decay of the latent HIV-1 reservoir2,3. However, the relative
extent to which the reservoir size and decay are controlled by viral
genetics still remains unknown.
The impact of viral genetic factors can be quantified as the viral
heritability, which is defined as the fraction of total phenotypic
variance explained by genetic factors. It ranges from 0% when
genetic factors do not contribute to the phenotypic variance, to
100% when genetic factors explain the entire phenotypic var-
iance23. The estimation of heritability depends on the partitioning
of the observed variance into contributions from environmental
factors and genetic factors. Heritability can be estimated using
resemblance estimators, which measure the relative trait-
similarity within transmission clusters. Established methods
include parent–offspring (PO) regression24–28 and analysis of
variance with mixed-effect models29,30. Additionally, phyloge-
netic comparative methods can also be used to estimate herit-
ability by measuring the association between observed trait values
from individuals and their transmission tree inferred from
pathogen sequences24,25. Common approaches include phyloge-
netic mixed models with an underlying Brownian motion process
(PMM)31–34 and phylogenetic mixed models with an underlying
Ornstein Uhlenbeck process (POUMM)28,30,35–37.
Most of these methods have been applied to estimate the
heritability of HIV-1 related phenotypes. Among these, the
influence of viral genetics on the SPVL has been the main focus of
attention (see28 and references therein). Generally, the consensus
has been achieved that SPVL is heritable, with heritability esti-
mates of 20–30% in different populations. Studies investigating
the heritability of the CD4+ T cell decline, which is the most
relevant measure of progression to AIDS, reported relatively low
heritability estimates of 10–20%36,37. The heritability of the
antibody response induced by an HIV infection has been esti-
mated to be around 10–15% based on mixed-effect Tobit
models38.
In this study, we investigate the heritability of the HIV-1
reservoir size and long-term decay using viral sequences and total
HIV-1 DNA measurements from Swiss HIV Cohort Study
(SHCS) participants infected with HIV-1 subtype B. Total HIV-1
DNA was found to be a sensitive, clinically relevant HIV-
reservoir marker which can be determined for large patient
populations3,19,39,40. Both partial pol Sanger sequences, which
were obtained for genotypic resistance testing, and viral near full-
length genome sequences are considered to increase the resolu-
tion of our estimates. To avoid potential bias introduced by a
single model, we explore both non-parametric (mixed-effect
model) and parametric (phylogenetic mixed model assuming a
trait evolution according to the BM and OU process) models.
Further, we adjust our analysis for a broad range of viral and host
characteristics known to influence the size and the decay of the
HIV-1 reservoir.
Results
Study population. We assessed the heritability of the HIV-1
reservoir size and decay slope in people living with HIV under
long-term suppressive combination ART. HIV-1 reservoir was
measured using total HIV-1 DNA measurements, a sensitive
marker for the HIV-1 reservoir. The analysis was performed on
the basis of the transmission network of 610 well-characterized
patients infected with HIV-1 subtype B enrolled in the SHCS
(Table 1).
From 1057 individuals enrolled in the SHCS with successfully
quantified total HIV-1 DNA at least ~1.5, ~3.5, and ~5.4 years
after the initiation of ART, we identified 475 individuals with
available next generation sequences (NGS) of viral near full-
length genome (denoted as population A0) and 869 individuals
with available Sanger sequences of partial pol region obtained for
genotypic resistance testing (GRT) (denoted as population B0)
(Fig. 1).
Considering the inter-subtype heterogeneity of HIV-1, we
restricted our study populations to individuals infected with HIV-
1 subtype B strains, which were 351 individuals with available
NGS sequences (denoted as population A) and 610 individuals
with available Sanger sequences (denoted as population B)
(Fig. 1). In the larger population (population B), 532 (87.2%)
were male and 403 (66.1%) were men who have sex with men
(MSM). 348 (99.1%) patients in the smaller population A also
belonged to population B and population A had comparable
characteristics to population B (Table 1). We additionally
performed sensitivity analyses on the full datasets (population
A0 and B0) including all HIV-1 subtypes (Supplementary
Table 1).
To estimate the heritability using mixed-effect models, we
extracted transmission clusters from phylogenies such that the
maximum phylogenetic distance within the cluster was not larger
than the pre-defined threshold. The number of extracted
transmission clusters varied with different thresholds and
different types of sequences used for phylogenetic inference
(Supplementary Table 2). In particular, applying phylogenetic
distance threshold of 0.04, 0.05, 0.06, and 0.09 substitutions per
site for sequences obtained by NGS and comparable distance
threshold levels of 0.01, 0.02, 0.03, and 0.045 for partial pol
sequences (explanatory plot see Supplementary Fig. 1), we
extracted 4, 11, 20, and 30 transmission clusters (8, 23, 44, and
74 patients) from the phylogeny of viral near full-length genome
sequences in population A, and 12, 30, 40, and 61 transmission
clusters (24, 65, 89, and 143 patients) from the phylogeny of
partial pol sequences in population B.
Heritability estimates for HIV-1 reservoir size. We found a
moderate but significant heritability of the HIV-1 reservoir size
~1.5 years after the initiation of ART using the viral near full-
length genome sequences from population A (Fig. 2). Mixed-
effect models yielded unadjusted heritability estimates which
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varied depending on the phylogenetic distance threshold, but
which were consistently larger than zero (23–32%). Using the R
package POUMM, we estimated the unadjusted heritability to be
24% [17%, 29%] based on the OU model and 10% [6%, 15%]
based on the BM model. The discrepancy of these estimates is
consistent with the known tendency of BM models (which are a
special case of OU model ignoring stabilizing selection) to pro-
vide lower heritability estimates than the OU models28. More-
over, even the estimates using OU model should be interpreted as
the lower bound for heritability, because any error due to poor fit
of the OU model, noise in HIV-1 reservoir measurement and
noise in the phylogeny will inflate the parameter σe(scaled
environmental variance), and hence implies that the obtained
estimates underestimate the true heritability28.
As clustered individuals tend to be clinically or demographi-
cally similar, unadjusted heritability estimates could potentially be
inflated41. Accordingly, adjustment for potential clinical and
demographical covariables lowered the heritability estimates for
BM and OU models; however, it increased the estimates for the
mixed-effect model: Upon adjustment for covariables, heritability
estimates derived using near full-length genome sequences from
the OU model decreased from 24 to 21%, stayed at 10% for the
BM model and increased for all mixed-effect model thresholds to
values between 29 and 78%. For partial pol sequences estimates
decreased from 12 to 7% for the OU model, from 3 to 2% for the
BM model, and from 69 to 57% for the strictest ME threshold.
For all other ME thresholds, adjusting for covariables increased
the heritability estimates to values between 25 and 61% (Fig. 2).
Generally, while broader confidence intervals for heritability were
obtained in the adjusted models, adjusted and unadjusted
estimates were qualitatively consistent for HIV-1 reservoir size.
We further compared the adjusted heritability estimates with
genetic information in different genes using the mixed-effect
model. In this sensitivity analysis, large variations in heritability
estimates using different genes and phylogenetic distance thresh-
olds were observed (Supplementary Fig. 2); however, in general,
the heritability estimates increased if the distance threshold was
lowered.
Next, we estimated the heritability of the HIV-1 reservoir size
in the larger study population (population B), in which partial pol
sequences from Sanger sequencing were used (Fig. 2). Mixed-
effect models yielded heritability estimates that were strongly
dependent on the phylogenetic distance threshold, ranging from
24 to 69% (unadjusted) and from 25 to 57% (adjusted). The OU
model yielded a lower heritability estimate of 12% [6%, 25%]
(unadjusted) and 7% [3%,12%] (adjusted) and the BM model also
yielded a lower estimate of 3% [2%,10%] (unadjusted) and 2%
[1%,7%] (adjusted). Broadening our analysis to the full datasets
with all HIV-1 subtypes included (Population A0 and B0) yielded
overall slightly lower heritability estimates (Supplementary Fig. 3),
which was expected considering the reduced homogeneity within
the larger group. Further, heritability estimates from the
phylogenies inferred from the overlapping fraction of population
A and B yielded similar estimates, thus the difference in study
Table 1 Patient characteristics.
Population A Population B
Sequenced HIV-1 genomic region Near full-length Partial pol
n 351 610
Age at first HIV-1 DNA sample, in years (median [IQR]) 42 [37,48] 43 [37,48]
Ethnicity (%) White 333 (94.87) 566 (92.79)
Non-white 18 (5.13) 44 (7.21)
Sex (%) Male 307 (87.46) 532 (87.21)
Female 44 (12.54) 78 (12.79)
Transmission group by sex (%) MSM 247 (70.37) 403 (66.07)
HET male 33 (9.4) 76 (12.46)
HET female 31 (8.83) 50 (8.2)
PWID male 22 (6.27) 37 (6.07)
PWID female 8 (2.28) 20 (3.28)
Other male 6 (1.71) 17 (2.79)
Other female 4 (1.14) 7 (1.15)
Time of untreated HIV-1 infection, in years (%) <1 43 (12.25) 100 (16.39)
1–3 51 (14.53) 82 (13.44)
3–5 90 (25.64) 150 (24.59)
5–7 61 (17.38) 104 (17.05)
>7 106 (30.2) 174 (28.52)
Time on ART at first HIV-1 DNA sample, in years (median [IQR]) 1.5 [1.3,1.7] 1.5 [1.3–1.7]
Time from ART initiation to below <50 HIV-1 RNA copies/ml,
in years (median [IQR])
0.3 [0.2,0.5] 0.3 [0.2,0.5]
CD4+ cell count pre-ART/μl blood (median [IQR]) 215 [130, 286] 214 [123, 299]
log 10 HIV-1 plasma RNA pre-ART/ml plasma (median [IQR]) 5.0 [4.5, 5.4] 4.9 [4.4,5.4]
HIV-1 RNA (180 days after ART initiation - 1st HIV-1 DNA sample) (%) <50 copies/ml 273 (77.78) 472 (77.38)
Viral blips 48 (13.68) 82 (13.44)
Low level viremia 27 (7.69) 53 (8.69)
HIV-1 RNA (1st - 3rd HIV-1 DNA sample) (%) <50 copies/ml 232 (66.1) 407 (66.72)
Viral blips 88 (25.07) 154 (25.25)
Low level viremia 31 (8.83) 49 (8.03)
Patient characteristics in population A (with available viral near full-length NGS sequences obtained from HIV-1 plasma RNA) and population B (with available partial pol Sanger sequences obtained from
HIV-1 plasma RNA).
The time of untreated HIV-1 infection was calculated using the estimated HIV-1 infection dates. Pre-ART log10 HIV-1 RNA copies/ml plasma and pre-ART CD4+ cell count/μl blood refer to the last
laboratory values available before initiation of ART. Transmission group stratified by sex indicates the self-reported route of infection (men who have sex with men (MSM), heterosexual (HET), people
who inject drugs (PWID), and other (including unknown, transfusions, and perinatal transmission)).
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populations had no significant influence in our estimates
(Supplementary Fig. 4). Generally, heritability estimates using
partial pol sequences were qualitatively consistent with estimates
using viral near full-length genome sequences.
Overall, we found that viral genetics explained a part of the
HIV-1 reservoir size variability, which was dependent on the
heritability estimator and dataset choice, but remained at 10% or
above for all near-full HIV-1 genome-sequence approaches
(Fig. 2). This indicated that the HIV-1 reservoir size was heritable
in our study population.
Heritability estimates for HIV-1 reservoir decay slope. Using
viral near full-length genome NGS sequences, we found tentative
evidence that the HIV-1 reservoir decay slope was heritable in our
study population A (Fig. 3) with estimates ranging from 3 to 85%
(Fig. 3). The adjusted mixed-effect model estimates even ranged
from 30 to 77%. The OU model yielded heritability estimates of
23% [9%, 40%] (unadjusted) and 10% [5%, 26%] (adjusted) and
the BM model yielded heritability estimates of 3% [0%, 3%]
(unadjusted) and 3% [1%, 4%] (adjusted). Similar to heritability
estimates for HIV-1 reservoir size, adjustment for covariables
increased the confidence intervals while yielding estimates com-
parable to the unadjusted values.
By contrast, using phylogenies inferred from partial pol Sanger
sequences of population B, all unadjusted and adjusted
heritability estimates were close to zero across different models
(Fig. 3). Broadening our analysis to the full datasets with all HIV-
1 subtypes included (Population B0) yielded no relevant changes
in heritability estimates derived using partial pol Sanger sequences
(Supplementary Fig. 5).
The difference in heritability estimates using viral near full-
length genome NGS sequences and partial pol Sanger sequences
was not due to the difference in study populations (Supple-
mentary Fig. 6). Further, using mixed-effect models, we
compared the heritability estimates using phylogenies built
from different genomic regions using near-full-length NGS
sequences (Supplementary Fig. 7). The estimates using partial
pol NGS sequences were zero for all thresholds, which was
consistent with the estimates derived using partial pol Sanger
sequences. However, we found positive heritability estimates
using gag and env sequences. These estimates were above 13%
except for the estimate using gag sequences under the most
liberal mixed-effect model threshold. The difference across the
genomic regions explained the overall higher estimates using
near-full-length viral genome sequences compared to partial pol
sequences.
1382 individuals
Received ≥3 PBMC samples (mandatory1st–3rd time point)
1166 individuals
Successful total HIV-1 DNA quantification in ≥3 PBMC
samples (mandatory1st–3rd time point)
1057 individuals
1932 individuals
Exclusion criteria:
start on less potent ART regimens, i.e., mono- or dual
therapy, less potent/unboosted PI (NFV, SQV, etc.)
Inclusion criteria:
HIV-1 infection
receiving ART for ≥5 years
no treatment interruption of >7 days
no virological failure, defined as two consecutive 
measurements >200 HIV-1 RNA copies/ml plasma 
PBMC available for three time points: 1.5 +/– 0.5 years, 3.5
+/– 0.5 years, and 5.5 +/– 1 years after initiating first-line
ART 
4th PBMC sample, latest time point available if receiving
ART for ≥8 years (optional)
18,688 individuals (Swiss HIV Cohort Study, 19/12/2014)
Population A0
475 individuals
Sanger sequencing of partial pol
region obtained for genotypic
resistance testing (GRT)
NGS sequencing of the near full-length
genome from plasma at the latest
sample before the initiation of ART
Population B0
869 individuals
Population B
610 individuals
Population A
351 individuals
Infected with HIV-1 subtype B Infected with HIV-1 subtype B
Fig. 1 Patient inclusion flowchart. ART antiretroviral therapy, PBMC peripheral blood mononuclear cells.
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Goodness of fit. We compared the goodness of fit of all three
models with the null model, which is given by a simple linear
regression model assuming no correlation between patients on
the phylogeny (Supplementary Tables 3 and 4). The null model
would outperform other models if no heritability was present. In
line with the reported heritability estimates, we found that all
heritability estimators (i.e., BM, OU, or mixed-effect model)
provided a better fit compared to the null model, for HIV-1
reservoir size using both sequence types (partial pol and near-full
length), and for HIV-1 reservoir decay using near full-length
genome sequences. In these cases, the mixed-effect model with
either the strictest or the most liberal threshold provided the
lowest AIC, except for the unadjusted heritability estimate for
HIV-1 reservoir size using partial pol sequences, where the OU
model provided the best fit. By contrast, for HIV-1 reservoir
decay slope with partial pol sequences, the null model provided
the best fit, which indicated zero heritability in this case.
The comparison with the null model also provides an
alternative approach to determine the significance of the viral
heritability in the mixed-effect model (Supplementary Tables 5,
6): Depending on the phylogenetic distance threshold, different
results were observed, which was likely due to the trade-off
between the statistical power and the accuracy of the transmission
cluster definition: Overall, in accordance with the positive
heritability found for HIV-1 reservoir size using nearfull-length
genomes and partial pol sequences and for reservoir decay using
nearfull-length genome sequences, we observed significant
random effects. By contrast, for reservoir decay and Sanger
partial pol sequences, where we reported no heritability, no
significant random effects were found.
Among the phylogenetic mixed models, the difference
between the fit of the BM and OU model was relatively small
3:01<AICOU  AICBM<3:44ð Þ in our study. While the OU
model provided a lower AIC compared to null model in some
cases, we found that the likelihood surface was relatively flat
across the model parameters, selection strength α and unit-time
variance σ, in most cases (Supplementary Figs. 8, 9). The two
parameters α and σ were strongly correlated with each other.
According to the Markov-Chain-Monte-Carlo (MCMC) uni-
variate model density plots (Supplementary Figs. 8, 9), there
was a close match between prior and posterior distributions for
the parameters α and σ, while the posterior samples were
notably distinct from the prior for the parameter θ (global
optimum level) and σe (scaled environmental variance). This
suggested a lack of signal in some of our datasets for some of
the OU parameters, i.e., OU models were in these cases not
informed well enough by our data. Thus, we suggest being
cautious about the parameter-estimates that are based on the
OU models, in particular, for the selection strength parameter α
and the unit-time variance parameter σ. Detailed discussion
Genomic region
NGS near
full-length genome
sequences
Sanger
partial pol
sequences
Model
OU
BM
ME
OU
BM
ME
Threshold
−
−
0.09
0.06
0.05
0.04
−
−
0.045
0.03
0.02
0.01
N
350
347
350
347
74
73
44
44
23
23
8
8
596
593
596
593
133
138
82
85
62
62
23
23
Heritability (%)
24 [17, 29]
21 [15, 26]
10 [ 6, 15]
10 [ 5, 14]
25 [19, 27]
29 [20, 33]
24 [15, 44]
34 [16, 68]
32 [17, 54]
57 [35, 91]
23 [ 9, 38]
78 [ 0, 100]
12 [ 6, 25]
7 [ 3, 12]
3 [ 2, 10]
2 [ 1,  7]
24 [11, 32]
25 [10, 38]
35 [16, 42]
48 [14, 59]
38 [19, 51]
61 [25, 79]
69 [ 6, 72]
57 [ 6, 86]
0 0.05 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 1
Heritability estimates for HIV-1 reservoir size
Unadjusted
Adjusted for covariables
Fig. 2 Heritability estimates for HIV-1 reservoir size based on the phylogenies built from near full-length HIV-1 genome NGS sequences and partial pol
Sanger sequences. OU: Ornstein Uhlenbeck model. BM: Brownian motion model. ME: Mixed-effect model with corresponding phylogenetic distance
threshold (substitutions per site). N: Number of patients included in the analysis. Patients with incomplete information of potential covariables were
excluded. For BM and OU, all eligible patients from the tree were included while for mixed-effect model, only patients in the extracted transmission clusters
were included. Black dots and black confidence intervals show the heritability estimates adjusted for covariables while blue rectangles and gray confidence
intervals show the unadjusted estimates. 95% confidence intervals are shown in square brackets.
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and interpretation of the estimates from phylogenetic mixed
models can be found in the Supplementary Discussion.
Discussion
This work represents, to the best of our knowledge, the first study
to estimate the heritability of the HIV-1 reservoir size and decay
over extensive follow-up periods in a well-characterized popula-
tion-based cohort of over 600 individuals infected with HIV-1
subtype B (Figs. 2, 3), as well as a broader population of over 800
individuals infected with diverse HIV-1 subtypes (Supplementary
Figs. 3, 5). The size of our cohort enabled us to achieve estimates
with high statistical support, while the extensive data of the
underlying SHCS allowed to correct for many known and sus-
pected confounders. We found that a moderate but significant
fraction of the HIV-1 reservoir size at ~1.5 years after the
initiation of ART was explained by viral genetic factors. Addi-
tionally, a tentative signal was also found for the decay of the
viral reservoir 1.5-5.4 years after the initiation of ART using full-
genome sequences, indicating that it was heritable in the cor-
responding study population. One major strength of our study is
that the wide range of applied methods reached qualitatively
consistent heritability estimates with overlapping confidence
intervals between methods. In that sense, our findings were
qualitatively robust with respect to potential confounding factors,
difference in sub-datasets analyzed, a wide range of phylogenetic
distance thresholds, discrepancies between model assumptions,
and potential sequencing errors.
Explicitly specifying and modeling environmental effects can
reduce the upward bias in heritability estimates42. All methods
used in our study allowed adjustment for the effects brought by
viral and host characteristics. Generally, adjusting for covariables
lowered or left unchanged heritability estimates derived with the
OU and BM model in most cases (except the slope heritability
estimate derived with the BM model using pol sequences) and
increased heritability estimates derived with the ME model
(except for heritability estimates derived with the strictest ME
threshold). This indicates that overall, the inclusion of the cov-
ariables led to more complex models resulting in higher uncer-
tainties, but reduced potential confounding by other covariables
such as pre-treatment virus load which is known to affect the
HIV-1 reservoir but can also cluster on the viral phylogeny.
Among potential viral and host characteristics that could
influence HIV-1 reservoir size and its long-term dynamics, SPVL
is expected to be of most importance. Consensus has been
achieved that SPVL had a heritability of around 20–30%28. In our
analysis, we used the last log 10 HIV-1 plasma RNA pre-ART/ml
plasma values available before initiation of ART (RNApreART) as
a substitute for SPVL for the following reasons: (1) SPVL can only
be calculated if patients start treatment during chronic phase. In
Genomic region
NGS near
full-length genome
sequences
Sanger
partial pol
sequences
Model
OU
BM
ME
OU
BM
ME
Threshold
−
−
0.09
0.06
0.05
0.04
−
−
0.045
0.03
0.02
0.01
N
350
350
350
350
74
74
44
44
23
23
8
8
596
596
596
596
133
133
82
82
62
62
23
23
Heritability (%)
23 [ 9, 40]
10 [ 5, 26]
3 [ 0,  3]
3 [ 1,  4]
22 [ 1, 21]
30 [ 0, 37]
30 [ 2, 54]
40 [ 0, 56]
62 [34, 78]
76 [ 0, 83]
85 [64, 85]
77 [23, 100]
1 [ 0,  4]
1 [ 0,  2]
1 [ 0,  1]
2 [ 0,  1]
0 [ 0,  2]
0 [ 0,  1]
0 [ 0,  8]
0 [ 0,  0]
0 [ 0, 16]
0 [ 0,  0]
0 [ 0, 34]
0 [ 0, 18]
0 0.05 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 1
Heritability estimates for HIV-1 reservoir decay slope
Unadjusted
Adjusted for covariables
Fig. 3 Heritability estimates for HIV-1 reservoir decay slope based on phylogenies built from near full-length HIV-1 genome NGS sequences and
partial pol Sanger sequences. OU: Ornstein Uhlenbeck model. BM: Brownian motion model. ME: Mixed-effect model with corresponding phylogenetic
distance threshold (substitutions per site). N: Number of patients included in the analysis. Patients with incomplete information of potential covariables
were excluded. For BM and OU, all eligible patients from the tree were included while for mixed-effect model, only patients in the extracted transmission
clusters were included. Black dots and black confidence intervals show the heritability estimates adjusted for covariables while blue rectangles and gray
confidence intervals show the unadjusted estimates. 95% confidence intervals are shown in square brackets.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19198-7
6 NATURE COMMUNICATIONS |         (2020) 11:5542 | https://doi.org/10.1038/s41467-020-19198-7 | www.nature.com/naturecommunications
our study, around 20% of patients started treatment during acute
phase, so if SPVL was used, we would lose those 20% of patients.
(2) More measurement and calculation errors can be introduced
during the approximation and calculation of SPVL. (3) RNA-
preART could be random across population considering the
different stages where patients started treatment. However, as the
heritability estimate for RNApreART in our dataset was 20.9%,
and thus comparable to that of SPVL, we believe RNApreART
can be used as an approximation for SPVL as a potential
covariable36.
As the heritability estimates from the mixed-effect model are
highly dependent on the phylogenetic distance threshold, the
trade-off between the accuracy of the transmission cluster defi-
nition and statistical power is to be considered when interpreting
the results. While the liberal threshold could provide more sta-
tistical power because of a larger number of cluster members, the
underlying assumption that little or no evolution occurred within
clusters is more problematic with liberal thresholds and similarly
the evidence that they are linked through transmission is weaker.
Thus, considering a range of genetic distance thresholds is central
to this study. Many HIV cluster studies have identified the proper
thresholds for partial pol sequences43,44, e.g., 0.045 substitutions
per site as the upper bound, while no consensus has been
achieved regarding near full-length genome sequences. Thus, we
extrapolated the thresholds for near full-length genome sequences
from partial pol sequences (Supplementary Fig. 1), assuming that
both phylogenies shared the same partition of cherries by genetic
distance. Overall, the wide range of distance threshold that we
applied, yielded qualitatively consistent conclusions in our study,
thereby underlying the robustness of our results.
Phylogenetic mixed models involve the evolutionary process of
the trait according to a BM or OU process, respectively. More
statistical power can be provided as all patients on the phylogeny
are included in the analysis, compared with mixed-effect model
which only includes patients from identified transmission clus-
ters. However, we found a lack of signal in our dataset for some of
the model parameters, especially, the selection strength parameter
α and the unit-time variance parameter σ. Possible reasons
include the following: First, traits related with HIV-1 reservoir
may not undergo the assumed evolutionary process especially
under suppressive ART, which can naturally explain why the
model did not fit our data well. Second, as phylogenetic mixed
model optimization requires large sample size for better and
stable performance, especially for the OU model36, our data size
may have been too small compared to the ones that were used in
previous studies for estimating heritability of SPVL (more than
3000 individuals). Finally, signals may be obscured by noise in the
data introduced, for example, from incomplete and inaccurate
genetic information (sequencing and polymerase chain reaction
(PCR) errors) or from assay variability (total HIV-1 DNA
measurements).
In our study, heritability estimates varied based on whether
viral near full-length genome sequences or Sanger sequences were
used. For both mixed-effect and phylogenetic mixed models, the
difference which may influence heritability estimates lies in the
reconstruction of a phylogenetic tree close to the real transmis-
sion networks using different genes. In principle, recombination
can affect phylogenetic inference. Recombination may imply that
different genes have different evolutionary history, thus phylo-
genies inferred from the near full-length genome sequences could
be different from those inferred from partial pol genes45. A sen-
sitivity analysis showed that effects from inter-subtype recombi-
nation did not disrupt our heritability estimates (see
Supplementary Fig. 11), but still intra-subtype recombination
could influence our estimates. Apart from recombination, phy-
logenetic inference could also be influenced by potential
convergent evolution46, which describes the process that different
individuals can acquire similar phenotypes or genotypes under
similar environments, which can result in clustering of unrelated
patients on the phylogeny. We excluded the common resistance
mutation genes on pol, but mutations occurring on gag and env
could still play a role, e.g., cytotoxic T lymphocytes (CTLs) escape
mutations47. The extent to which these factors can influence the
heritability estimates using different genes would merit further
investigations.
In summary, the two datasets analyzed (near full-length gen-
ome sequences and partial pol sequences) represent a different
compromise between evolutionary information and sampling
density. Since heritability is a property of the population under
consideration, no numerical accordance between estimates from
the two populations should be expected. The advantage of the
partial pol (Sanger) dataset is a higher sample size and higher
sensitivity to obtain sequences also at lower viral loads due to the
shorter amplified and sequenced fragment. The advantage of our
NGS dataset is that it captures the near full-length HIV-1 gen-
ome, thereby allowing for a more exact phylogenetic recon-
struction, which is methodologically more correct. However, it is
a key strength of this study that different datasets were available,
systematically assessed and compared. This may build the basis
for further studies assessing the heritability of HIV-1 reservoir
phenotypes without having access to different sequencing
datasets.
Our study has some limitations. First, we used total HIV-1
DNA measured in peripheral blood mononuclear cells (PBMC)
samples as a proxy for the latent HIV-1 reservoir. As total HIV-1
DNA levels are higher than the HIV-1 reservoir of replication
competent latently infected cells, this is theoretically a limitation
of our study. However, we believe our choice is the optimal
compromise at this time: On the one hand, it has been shown that
total HIV-1 DNA measured in PBMC samples is a sensitive,
clinically relevant proxy for the HIV-1 reservoir3,39,40,48 that also
correlates well with the intact proviral DNA assay40. On the other
hand, the very recently described, sophisticated methods (quan-
titative viral outgrowth assay, tat/rev induced limiting dilution
assay etc) are not applicable to a cohort of over 600 longitudinally
sampled participants, as they are too time- and labor intensive
and/or require a high amount of cells, and thus, are only (pro-
spectively) applicable to selected individuals49,50. Such studies of
a few individuals, although highly interesting and important,
always bear the risk of strong selection bias implying that gen-
eralizability to the population level is often problematic. In con-
trast, total HIV-1 DNA can be determined in large populations
needed for heritability studies3,39,48.Thus, there is a trade-off
between the potential bias directly induced by the measurement
method and the bias indirectly induced by method’s restrictions
and limitations of the study population.
In addition, even though the study population represents the
largest cohort of patients with longitudinal HIV-1 reservoir
measurements so far, statistical power remained a major limita-
tion for several analyses: for the phylogenetic mixed model, the
total number of patients in transmission clusters was relatively
small compared with previous studies which estimated the her-
itability of other HIV-1 related traits28. This was in particular the
case for the stricter distance threshold. As a consequence, we
observed a large variability in heritability estimates across
methods and phylogenetic distance thresholds. As our study is
the first to determine the heritability of HIV-1 reservoir size and
decay, the true (“ground truth”) heritability of this trait remains
unknown and thus, a final conclusion on model performance is
impossible. Another limitation of our study is that the BM and
OU model did not fit our data well, which kept us from drawing
conclusions on the evolution of HIV-1 reservoir size and long-
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term decay on population levels. Further, we did not analyze the
impact of the diversity of viral populations on the HIV-1 reser-
voir phenotypes, which will merit further investigations in future
studies. Finally, as for all molecular epidemiology and
comparative-method studies, the validity of our conclusions
depends on the accuracy of the phylogenetic inference from
sequences, which could be influenced by many factors, such as
within-host evolution, limited genetic information contained in
short sequences (partial pol), recombination and convergent
evolution. However, we do not expect this to have a substantial
influence on our estimates and in particular our heritability
estimates are conservative in the sense that phylogenetic error
leads to an underestimation of heritability.
A great inter-individual variability in the number of latently
HIV-1 infected cells and long-term dynamics under suppressive
treatment was reported across different studies5,7,51,52. Quantifying
the contribution of viral genetic factors to this variability is of
importance both, from a basic and clinical science perspective, and
may inform future reservoir and cure studies. In our study, we find
evidence for a moderate but significant heritability of the HIV-1
reservoir size 1.5 years after initiation of ART and more tentative
evidence for the heritability of the long-term dynamics of the HIV-1
reservoir decay. While the mechanisms underlying this heritability
remain to be defined, our results indicate that the infecting HIV
strain should be taken into consideration in future efforts to
cure HIV.
Methods
The Swiss HIV Cohort Study. The SHCS is a nationwide, prospective observa-
tional study founded in 1988 and enrolling HIV-infected adults of all transmission
groups53. Clinical and laboratory data are collected every 3–6 months and plasma
and cell samples are stored every 6–12 months. More than 75% of all HIV-1
infected individuals registered in Switzerland and receiving ART are enrolled in the
SHCS53. The current study participants were included when they fulfilled the
following inclusion criteria: (1) start on potent ART regimen (i.e., no mono- or
dual therapy, no less potent/unboosted PI (NFV, SQV etc.), (2) no treatment
interruption of >7 days, (3) no virologic failure as defined by two consecutive viral
load measurements >200 HIV-1 RNA copies/ ml plasma, (4) available cell samples
during ART, (5) either A. NGS sequencing of the full genome from plasma at the
latest sample before the initiation of ART or B. Sanger sequencing of partial pol
region obtained from plasma for genotypic resistance testing (GRT) and 6) infected
with HIV-1 subtype B (Table 1, Fig. 1). The subtypes were determined using partial
pol Sanger sequences. We additionally identified 12 potential recombinants using
Comet54 on near full-length genome sequences and did a sensitivity analysis
excluding those patients (Supplementary Fig. 11). The SHCS has been approved by
the ethics committee of the participating institutions and written informed consent
was obtained from all participants.
HIV-1 reservoir size and decay. We focused on the following two distinct phe-
notypes which were pre-defined in the previous study3: 1. The HIV-1 reservoir size,
i.e., the total HIV-1 DNA level 1.5 years after initiation of ART and 2. The HIV-1
reservoir long-term dynamics under ART, i.e., the decay slope of the total HIV-1 DNA
from 1.5 to 5.4 years. Total HIV-1 DNA data were obtained from the dataset estab-
lished in our previous study3. In this study PBMCs at ~1.5, ~3.5, and ~5.4 years after
initiation of ART were collected, cellular DNA was extracted, total HIV-1 DNA was
quantified, and reservoir decay rates were calculated (see subsections “Cells”, “Geno-
mic DNA extraction and fragmentation”, and “Quantification of total HIV-1 DNA by
droplet digital PCR” in the Methods section of ref. 3). The distributions of HIV-1
reservoir size and decay in Population A and B are displayed in Supplementary Fig. 12.
Phylogenetic tree construction. We performed our heritability estimation for two
distinct populations infected with HIV-1 subtype B (population A. of patients with
viral near full-length genome NGS sequences available and population B. of
patients with available GRT sequences) and accordingly with different phylogenies.
For the construction of maximum likelihood phylogenetic trees, we included the
partial pol Sanger sequences from the positions 2253–3870 and viral near full-
length genome NGS sequences.
For partial pol sequences, we chose the sequence from the SHCS resistance
database closest to the initiation of ART, if more than one sequence per patient was
available, while near full-length genome NGS sequencing was performed
systematically using the last plasma sample available before the initiation of ART for
each patient. Sanger sequences were aligned to an HXB2 reference genome using
MUSCLE55. We used consensus sequences, which were derived from NGS data
(determined as described in Supplementary Method) by the analysis pipeline V-
pipe56. In this pipeline, NGS reads were preprocessed with PRINSEQ v0.20.457. We
then aligned the preprocessed reads to an HXB2 reference genome and generated
the consensus sequences with a majority vote rule using ngshmmalign. Low
coverage positions (<40 reads) were excluded and only NGS consensus sequences
larger than 5000 bp were selected. For all sequences, insertions relative to HXB2 and
resistance mutations according to the Stanford (http://hivdb.stanford.edu/) and
International Antiviral Society-USA (https://www.iasusa.org/) lists were removed,
and positions with many gaps were eliminated by trimAl58. Conserved blocks from
multiple alignments were selected for phylogenetic analysis.
Phylogenetic tree construction was performed using the maximum likelihood
algorithm RAxML version 8 with the GTRCAT model59. One hundred Bootstrap
trees were constructed simultaneously with built-in options. Phylogenetic trees
were inferred separately on five sets of sequences: the gag, pol, env and near full-
length genome NGS sequences of population A and the partial pol-sequences of
population B. All trees were rooted with an outgroup of HIV-1 subtype D
sequences. To avoid the risk brought by rooting with distant outgroup, we
additionally performed a sensitivity analysis using LSD-0.260 to find the root of the
tree (Supplementary Figs. 13, 14).
Extraction of transmission clusters. We identified potential transmission clusters
such that the maximum phylogenetic distance within the cluster was no larger than
pre-defined threshold, using the R package APE61 and custom scripts. For phy-
logenies built with partial pol-sequences, phylogenetic distance thresholds of 0.01,
0.02, 0.03, 0.045 substitutions per site were applied. For HIV-1 viral near full-length
genome sequences, no consensus was achieved regarding the phylogenetic distance
threshold for defining a transmission group. In our analysis, they were chosen such
that they include the same percentage of cherries compared with using phylogeny
built from partial pol Sanger sequences and applying cutoff of 0.01, 0.02, 0.03, and
0.045 (explanatory plot in Supplementary Fig. 2). The derived phylogenetic dis-
tance threshold for full-genome sequences were 0.04, 0.05, 0.06, 0.09 substitutions
per site. Using similar methods, the derived thresholds for gag sequences were 0.01,
0.02, 0.03, and 0.05 and for env sequences these were 0.03, 0.05, 0.07, and
0.09 substitutions per site.
Heritability estimates. Heritability of the considered phenotypes was estimated
with three models, mixed-effect model and phylogenetic mixed models with
underlying Brownian motion or Ornstein Uhlenbeck process. Trait value data was
fitted with a mixed-effect model using the R package NLME62 (lme function,
restricted maximum likelihood) and heritability was determined as the ratio of the
between-cluster variance and the total variance.
Further, we applied phylogenetic mixed models to estimate the heritability of
the HIV-1 reservoir traits. These models are widely used to estimate heritability
from a phylogenetic tree, based on the assumptions that the trait evolved along the
tree according to Brownian motion (BM) or Ornstein Uhlenbeck (OU) model
respectively. In the BM model a trait is assumed to evolve according to the
stochastic process σdWt, where ðWtÞðt ≥ 0Þ denotes BM and accounts for
randomness in the divergence of a trait, and σ scales the magnitude of fluctuations.
The BM model is usually interpreted as a random unconstrained neutral evolution
process. As an extension of Brownian motion, the Ornstein Uhlenbeck model adds
an additional stabilizing selection towards the long-term optimal trait value. In the
OU model,ðXtÞðt ≥ 0Þ is defined as
dXt ¼ α θ  Xð Þdt þ σdWt ;
where θ denotes the global optimum level and α the strength of selection.
The R package POUMM28 was used for fitting the OU and BM model with
Bayesian inference and maximum likelihood optimization, respectively. We
reported in the main text the empirical (time-independent) heritability estimates
H2e from the package. As the package does not provide options to adjust for
covariables, we performed a multivariate linear regression first to adjust for
covariables and then took the residuals from the regression as trait value input into
the optimization37. We also applied similar methods described by Blanquart
et al.36, which directly incorporated adjustment for covariables in maximum
likelihood estimation for fitting the models (Supplementary Tables 3,4;
Supplementary Figs. 8, 9). Using this method, the upper limit of α was set as 10,
which was the same as implemented in Blanquart et al.36.
Estimates from Bayesian inference were reported in the main text and estimates
from maximum likelihood estimates were included in (Supplementary Tables 3, 4;
Supplementary Fig. 8, 9). To assess the uncertainties in the phylogenetic tree
interference and heritability estimation, all confidence intervals were derived based
on the distribution of the estimates across the 100 bootstrapped trees.
Adjustment for viral and host covariables. Viral and host characteristics which
were found to be associated with HIV-1 reservoir size and decay slope in previous
work3 or in the current populaiton were adjusted for in the analysis. For HIV-1
reservoir size, we adjusted for transmission group, sex, ethnicity, age, time on ART,
time to suppression, initiation of ART in acute/chronic infection, RNA and CD4
pre-ART, and prior viral blips. For reservoir decay slope, we adjusted for HIV-1
reservoir size, treatment center, time to suppression, CD4 pre-ART and viral blips.
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We performed a sensitivity analysis to relax the linearity assumption made
for continuous covariables. In these sensitivity analyses, we used polynomial
splines (bs() function in the r package splines63) for all numerical variables
(Supplementary Figs. 15, 16). Further, we performed a sensitivity analysis using
an adjustment based on residuals of the full dataset (N = 869), thereby avoiding
the inclusion of many covariables in an already small dataset and using the best
information available in the full population for adjustment (Supplementary
Figs. 17,18).
We defined viral load to be suppressed when all measurements were <50 HIV-1
RNA copies/ml plasma. We defined viral blips to be present when there were
measurements ≥50 HIV-1 RNA copies/ml plasma, which were preceded and
followed by measurements <50 HIV-1 RNA copies/ml plasma. Any subsequent
viral load measurement ≥50 HIV-1 RNA copies/ml plasma within 30 days of a viral
blip was considered to be part of the same viral blip64. Individuals who had
multiple consecutive viral load measurements ≥50 HIV-1 RNA copies/ml plasma
(without experiencing virological failure as defined by two consecutive viral load
measurements >200 HIV-1 RNA copies/ml plasma) were considered to exhibit
low-level viremia.
We determined the initiation of ART as occurring in acute/chronic infection
using the estimated HIV-1 infection date, which was estimated using a hierarchical
approach on the basis of indicators of varying reliability65. The following methods
were used with decreasing priority to yield the maximal accuracy for HIV-1
infection dates possible:
1. Defined HIV-1 primary infection: Either seroconversion dates (negative and
positive HIV-1 screening tests less than 1 year apart) or a diagnosis of a
primary infection were available as previously described66. We used the
midpoint between the dates of the negative and positive tests or, if known,
the date of the primary infection as the estimated HIV-1 infection date for
these individuals.
2. Defined recent HIV-1 infection: If genotypic HIV-1 drug resistance test
within the first year after diagnosis revealed low HIV-1 diversity (less than
0.5% of ambiguous nucleotides) and CD4+ cell counts were >200 cells/µl
blood at registration43,67,68, we interpreted these as recent HIV-1 infections
and used the diagnosis date as an estimate for the infection date.
3. HIV-1 infection date estimates based on a back-calculation method using
CD4+ cell counts and their slopes when available69.
4. For the remaining individuals, no accurate dating was available. For these
individuals the date of diagnosis was used as substitute for the HIV-1
infection date, which allowed us to define at least the minimum length of
HIV-1 infection.
Time to viral suppression was defined as the time from initiation of ART until
the first viral load below 50 copies/ml HIV-1 plasma RNA.
HIV-1 subtype was determined using the REGA HIV-1 subtyping tool70 and
COMET54.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The individual level datasets generated or analyzed during the current study do not fulfill
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